Interactions between remimazolam and propofol in combination with sufentanil for anesthesia during gastroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100052425

Enrollment

Unknown

Registered

2021-10-26

Start date

2021-01-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal diseases

Interventions

A:administered remimazolam in combination with 0.1 ug/kg sufentanil

B:administered propofol in combination with 0.1 ug/kg sufentanil

C:administered propofol in combination with 0.1 ug/kg sufentanil and 0.25 median effective dose (ED50) remimazolam

D:administered propofol in combination with 0.1 ug/kg sufentanil and 0.5 ED50 remimazolam

E:administered propofol in combination with 0.1 ug/kg sufentanil and 0.75 ED50 remimazolam

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients who had an American Society of Anesthesiologists physical status of I/II and were scheduled for gastrointestinal endoscopy were included in the study.

Exclusion criteria

Exclusion criteria: 1. Anemia (hemoglobin < 90 g/L); 2. Albumin levels < 30 g/L; 3. Platelet count < 50 x 10^9 /L; 4. Anticipated difficult airway; 5. Obvious respiratory or circulatory dysfunction before the procedure; 6. Severe neuropsychiatric disease; 7. Allergies or contraindications for the use of benzodiazepines, opioids, propofol, flumazenil, naloxone or other drugs and their components; 8. Taken similar drugs recently.

Design outcomes

Primary

Measure	Time frame
eyelash reflex;	—

Countries

China

Contacts

Public ContactSong Lyu

The Second Affiliated Hospital of Hainan Medical University

lssjk1@126.com+86 15203647221

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026